Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Combi-Neo
- 04 Nov 2019 Planned End Date changed from 31 Oct 2019 to 31 Oct 2022.
- 04 Nov 2019 Planned primary completion date changed from 31 Oct 2019 to 31 Oct 2022.
- 12 Dec 2018 Planned End Date changed from 1 Oct 2020 to 31 Oct 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History